Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine

Gene Therapy

Volumn 6, Issue 2, 1999, Pages 219-226

  Okada, H ^a,b   Giezeman Smits, K M ^a,b   Tahara, H ^a   Attanucci, J ^a,b   Fellows, W K ^a,b   Lotze, M T ^a   Chambers, W H ^a,b   Bozik, M E ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Gliomas; Herpes simplex virus thymidine kinase; Interleukin 4; Retroviral vectors; Tumor vaccine

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; GAMMA INTERFERON; GANCICLOVIR; INTERLEUKIN 4; THYMIDINE KINASE; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CELL PROTECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; GENE CASSETTE; GENE CONSTRUCT; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; IMMUNE RESPONSE; IMMUNIZATION; INTRACRANIAL TUMOR; IRRADIATION; NONHUMAN; PRIORITY JOURNAL; RAT; RETROVIRUS; RIBOSOME; SPLEEN CELL; SUBCUTANEOUS TISSUE TUMOR; TUMOR CELL;

ANIMALS; ANTIVIRAL AGENTS; BRAIN NEOPLASMS; CANCER VACCINES; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; GLIOMA; INTERFERON TYPE II; INTERLEUKIN-4; MALE; RATS; RATS, INBRED F344; RETROVIRIDAE; SPLEEN; THYMIDINE KINASE;

EID: 0032991779     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300798     Document Type: Article

References (34)

1. Murphy JB, Sturm E. Conditions determining the transplantability of tissues in the brain. Rockefeller Inst Med Res 1926; 21: 183-197.
2. Gordon LB et al. Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination. J Immunol 1997; 159: 2399-2408.
3. Mitchell MS. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol 1989; 7: 1701-1709.
4. DeMicco C. Immunology of central nervous system tumors (review). J Neuroimmunol 1989; 25: 93-108.
5. Kalman B, Lublin FD. Immunopathogenic mechanisms in experimental allergic encephalomyelitis (review). Curr Opin Neurol Neurosurg 1993; 6: 182-188.
6. + cell-mediated immunity against tumors located in the 'immunologically privileged' central nervous system. Proc Natl Acad Sci USA 1996; 93: 10399-10404.
7. Wakimoto H et al. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 1996; 56: 1828-1833.
8. Bozik ME, Chambers WH, Gilbert M, Lotze MT. Treatment of 9L gliosarcoma with IL-4 producing 9L vaccine. FASEB meeting 1996 (Abstr.).
9. Noelle R et al. Increased expression of Ia antigens on resting B cells. Proc Natl Acad Sci USA 1984; 81: 6149-6153.
10. Hu-Li J et al. B cell stimulatory factor I (interleukin 4) is a potent costimulant for normal resting T lymphocytes. J Exp Med 1987; 165: 157-161.
11. Kawakami Y, Rosenberg SA, Lotze MT. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med 1988; 168: 2183-2191.
12. Barks JL, McQuillan JJ, Iademarco MF. TNF-alpha and IL-4 synergistically increase vascular cell adhesion molecule-1 expression in cultured vascular smooth muscle cells. J Immunol 1997; 159: 4532-4538.
13. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57: 503-512.
14. + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J Immunol 1994; 153: 5659-5673.
15. Golumbek PT et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991; 254: 713-716.
16. Bozik ME et al. T-cell dependent intracerebral tumor regression of a 9L gliosarcoma expressing mIL-4 in a syngeneic host. Proc Annu Meet Am Assoc Cancer Res 1996; 36: A2800 (Abstr.).
17. Mayordomo JI et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nature Med 1995; 1: 1297-1302.
18. + progenitor cells. Exp Hematol 1998; 26: 63-72.
19. Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
20. Ram Z et al. In situ retroviral gene transfer for the treatment of brain tumors in rats. Cancer Res 1993; 53: 83-88.
21. Ram Z et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producer cells. Nature Med 1997; 3: 1354-1361.
22. Moolten FL. Tumor chemosensitivity conferred by inserted Herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
23. Barba D, Hardin J, Sadelain M, Gage FH. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 1994; 91: 4348-4352.
24. Chen SH et al. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res 1996; 56: 3758-3762.
25. Benedetti S et al. Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. Hum Gene Ther 1997; 8: 1345-1353.
26. Townsend SE, Su FW, Atherton JM, Allison JP. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 1994; 54: 6477-6483.
27. Allione A et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 1994; 54: 6022-6026.
28. Santodonato L et al. Cure of mice with established metastatic Friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon-alpha 1 and herpes simplex thymidine kinase followed by ganciclovir. Hum Gene Ther 1996; 7: 1-10.
29. Tahara H et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995; 154: 6466-6474.
30. Okada H et al. Gene therapy against an experimental glioma using adeno-associated virus vectors. Gene Therapy 1996; 3: 957-964.
31. Stoppacciaro A et al. Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines. Eur J Immunol 1997; 27: 2375-2382.
32. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
33. Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA 1988; 85: 6460-6464.
34. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90: 8392-8396.